Fig. 5: Either GW4869 administration to inhibit EVs release or STING deficiency improved the disease prognosis of murine colitis.
From: Extracellular vesicles package dsDNA to aggravate Crohn’s disease by activating the STING pathway
A–E Comparison of disease prognosis among six experimental murine models (n = 11–20/group). WT (GW4869 IP): to examine possible side effects of GW4869, GW4869 was administrated in normal wild-type mice. WT + DSS (GW4869 IP): Murine colitis models treated with GW4869. STING−/− + DSS: STING knockout (STING−/−) mice were employed and induced by DSS to establish colitis. Indicators of disease activity and severity were examined including A Disease activity index (DAI), B percent changes in body weight, C survival rate, D lengths and representative images of colons, E histological score of colons and representative colon H&E images. Data were displayed as mean values ± SD at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
